Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for?
Davie
A P
AP
McMurray
J J V
JJ
D001026:Coronary Artery Bypass / Q000191:economics; D003324:Coronary Artery Disease / Q000150:complications / Q000191:economics* / Q000628:therapy; D003327:Coronary Disease / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000191:economics; D005060:Europe / Q000453:epidemiology; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000191:economics / Q000627:therapeutic use; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban